Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anti-Obesity Effects of a Combination of Whole-Body Vibration Stimulus and Dietary D-Allulose on Rats Fed a High-Fat Diet.

Journal of nutritional science and vitaminology·2025

Same author

Effects of Dietary Allitol and D-Allulose on Body Fat Accumulation and Cecal Short-Chain Fatty Acid Production in Rats Fed a High-Fat Diet.

Journal of oleo science·2024

Same author

Long-Term Whole-Body Vibration Stimulus Decreases Body Fat Accumulation in Rats Fed a High-Fat Diet.

Journal of oleo science·2023

Same author

Safety evaluation and maximum use level for transient ingestion in humans of allitol.

Bioscience, biotechnology, and biochemistry·2023

Same author

Effects of Dietary Allitol on Body Fat Accumulation in Rats.

Journal of nutritional science and vitaminology·2022

Same author

Dietary D-Allulose Reduces Body Fat Accumulation in Rats with and without Medium-Chain Triacylglycerol Supplementation.

Journal of oleo science·2022

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Interaction between alpha-linolenic acid-enriched oil and ACE inhibitor concerning the decrease in blood pressure in

Tatsuhiro Matsuo¹, Kanako Yagi

¹Faculty of Agriculture, Kagawa University, Kagawa, Japan. matsuo@ag.kagawa-u.ac.jp

Journal of Oleo Science

|December 14, 2007

Summary

This summary is machine-generated.

Alpha-linolenic acid (ALA) and angiotensin-converting enzyme inhibitors (ACEI) both lower blood pressure. Combining ALA-enriched oil with ACEI in rats showed limited interaction but suggested safety for concurrent use.

Related Experiment Videos

Last Updated: Jul 9, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Area of Science:

Cardiovascular Research
Nutritional Science
Pharmacology

Background:

Alpha-linolenic acid (ALA) is a plant-derived omega-3 fatty acid with reported antihypertensive properties.
Angiotensin-converting enzyme inhibitors (ACEI) are a class of drugs widely used for managing hypertension.
Understanding potential interactions between dietary components like ALA and antihypertensive medications is crucial for patient safety and therapeutic efficacy.

Purpose of the Study:

To investigate the interaction between ALA-enriched oil and ACEI on blood pressure regulation in spontaneously hypertensive rats (SHR).
To assess the combined effect of ALA and ACEI on both systolic and diastolic blood pressure.
To evaluate the safety of co-administering ALA-rich foods with hypotensive agents.

Main Methods:

Administration of ALA-enriched oil, ACEI, or a combination of both to 7-week-old spontaneously hypertensive rats (SHR).
Monitoring and comparison of systolic and diastolic blood pressure levels before and after administration across different treatment groups.
Statistical analysis to determine significant changes and differences in blood pressure among the groups.

Main Results:

Systolic blood pressure significantly decreased in all groups (ALA-enriched oil, ACEI, and combination) compared to baseline.
Diastolic blood pressure showed a significant decrease only in the group receiving both ALA-enriched oil and ACEI.
No statistically significant differences in either systolic or diastolic blood pressure were observed among the three treatment groups post-administration.

Conclusions:

The interaction between ALA-enriched oil and ACEI regarding blood pressure reduction in SHR appears to be limited.
The findings suggest that consuming foods high in ALA in conjunction with antihypertensive medications is likely safe.
Further research may be warranted to fully elucidate the nuanced cardiovascular effects of combined ALA and ACEI therapy.